FDA recalls 3,655 Vitruvias thyroid tablet units: UAE pharmacies should check Lot 504950

Vitruvias Therapeutics has recalled 3,655 units of Thyroid Tablets, USP 30 mg after testing found possible super potency, a US action that UAE pharmacies and clinics should treat as a targeted stock-check alert rather than a confirmed local recall.

The highest-stakes readers are pharmacy operators, clinic COOs and medical directors. In Dubai, that means checking pharmacy inventory, patient-supplied medicines and endocrine prescribing workflows under Dubai Health Authority (DHA) oversight. In Abu Dhabi, the same checks sit with facilities licensed by the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, operators should verify requirements through the Ministry of Health and Prevention (MOHAP).

What the FDA notice says

The FDA recall notice, published on 24 August 2026, covers Lot 504950, NDC 69680-166-00, with an expiry date of 30 September 2026. The product was distributed in the US between 31 January 2025 and 30 September 2025. Vitruvias said 1,955 units had been sold.

"Consumption of superpotent Thyroid tablets can cause hyperthyroidism."
Vitruvias Therapeutics, FDA company announcement, 21 August 2026

The tablets are derived from porcine thyroid glands and contain both levothyroxine and liothyronine. The risk is overdose of thyroid hormone. FDA-listed symptoms include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate and heart rhythm disturbance. Vitruvias said it had received no adverse-event reports linked to the recall as of the announcement date.

Why UAE operators should care

The recall is US-specific on the published facts. That still matters in the UAE because thyroid medicines are chronic therapies, travellers carry personal supplies, and some patients arrive with prescriptions filled abroad. Dubai clinics should ask patients to bring thyroid medication bottles to appointments when thyroid-stimulating hormone results shift without a dose change. Abu Dhabi providers should apply the same check before changing a stable dose. MOHAP-regulated pharmacies should search by brand, NDC, lot number and expiry where imported or patient-returned medicines are presented.

Local operators should focus on four immediate checks:

• Search pharmacy stock and returned medicines for Lot 504950 and NDC 69680-166-00.
• Ask endocrine, obstetric and paediatric teams to flag patients taking US-sourced natural thyroid tablets.
• Record any suspected adverse reaction through the facility's pharmacovigilance process and the relevant UAE regulator.
• Check the MOHAP registered medical product directory before dispensing or substituting unfamiliar thyroid products.

For insurers, the issue is substitution control. Daman, Thiqa and Sukoon adjudicate pharmacy or outpatient claims across different networks and plans. A recall-driven switch may trigger a new physician order, prior authorisation or formulary review. Clinics should document the reason for any replacement, the lot number seen by the pharmacist, and the clinical rationale if thyroid function testing is ordered earlier than the routine interval.

Patient and pharmacy economics

The UAE price impact is likely modest for standard levothyroxine, but the clinical risk is higher than the invoice value. A commonly listed UAE product, Euthyrox 50 mcg 100 tablets, is listed at AED 20 by myAster and requires a prescription. Gulf Pharmacy lists Euthyrox 50 mcg 100 tablets at AED 20. Operators should verify current prices in their contracted pharmacy network because online prices, availability and insurer co-pay rules can change without notice.

The patient-safety risk is concentrated in older adults, pregnant women and infants, the same groups named in the FDA notice. UAE clinicians should avoid advising patients to stop thyroid therapy without a replacement plan. Abrupt interruption can push hypothyroid patients out of range, while continued use of a superpotent batch can create hyperthyroid symptoms and cardiac risk.

For the next 30 days, pharmacy chains and clinic groups should add Lot 504950 to dispensing audits, patient-call scripts and medication reconciliation forms. The practical route is simple: identify the bottle, confirm the lot, contact the prescriber, document the action and follow DHA, DOH or MOHAP instructions if a local safety circular is issued. Patients and operators looking for licensed pharmacy providers in the UAE should use the UAE Open Healthcare Directory and the relevant emirate regulator's facility directory.